Literature DB >> 9647236

A lambda 3' enhancer drives active and untemplated somatic hypermutation of a lambda 1 transgene.

Q Kong1, L Zhao, S Subbaiah, N Maizels.   

Abstract

Somatic hypermutation is a highly regulated process that targets mutations to the rearranged Ig genes. Little is known about the cis-elements required for somatic hypermutation of the lambda light chain gene. We have studied somatic hypermutation of a rearranged lambda 1 transgene under the control of either a lambda 2-4 or kappa 3' enhancer. The mutations in the transgenes were analyzed by sequencing DNA amplified from hypermutating Peyer's patch B cells. The results indicate that the lambda 3' enhancer can drive active hypermutation of a lambda 1 transgene in Peyer's patch cells. The lambda 1 transgene under analysis carried two marked V lambda 2 genes immediately upstream that could serve as sequence donors in possible gene conversion events. There was no evidence of sequence transfer to the hypermutated lambda 1 gene, suggesting that gene conversion is not a major mechanism for somatic hypermutation in mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9647236

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Breaksite batch mapping, a rapid method for assay and identification of DNA breaksites in mammalian cells.

Authors:  Q Kong; N Maizels
Journal:  Nucleic Acids Res       Date:  2001-03-15       Impact factor: 16.971

2.  DNA breaks in hypermutating immunoglobulin genes: evidence for a break-and-repair pathway of somatic hypermutation.

Authors:  Q Kong; N Maizels
Journal:  Genetics       Date:  2001-05       Impact factor: 4.562

3.  A cis-acting diversification activator both necessary and sufficient for AID-mediated hypermutation.

Authors:  Artem Blagodatski; Vera Batrak; Sabine Schmidl; Ulrike Schoetz; Randolph B Caldwell; Hiroshi Arakawa; Jean-Marie Buerstedde
Journal:  PLoS Genet       Date:  2009-01-09       Impact factor: 5.917

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.